Tholander B.; Koliadi A.; Botling J.; Dahlstrand H.; Von Heideman A.; Ahlström H.; Öberg K.; Ullenhag G. J. Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma. Upsala Journal of Medical Sciences, v. 125, n. 4, p. 325–329, 10 Oct. 2020.